A team from CNIO and CIEMAT eliminates cells that contain excessive copies of oncogenes using CRISPR gene editing. In cellular and animal models of neuroblastoma, small cell lung cancer and colon ...
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene ...
Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is ...
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, ...
A newly discovered gene switch may help turn chemotherapy-resistant pancreatic cancer into a treatable disease.
Extrachromosomal DNAs (ecDNAs) are circular DNA structures located in the nuclei of cells outside chromosomes. They were originally discovered in chromosome spreads of cells obtained from embryonal ...
Pancreatic cancer is notoriously hard to treat, often resisting therapies that target its most common mutations. Researchers have now uncovered a hidden three-part loop that fuels tumor growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results